Drug makers and investors are all in on the Chinese market, betting that there’s big profit to be made bringing innovative new drugs to patients who’ve historically had few options.
But there’s a crucial question looming: How are drug makers going to make money in a Chinese system that’s vastly different than that of the U.S.?
About the Author Reprints
Looks very interesting